GLAXO Intraday Analysis...

GLAXO Share Price

Open 2781.95 Change Price %
High 2834.00 1 Day 23.05 0.83
Low 2751.00 1 Week 60.60 2.20
Close 2808.90 1 Month 391.75 16.21
Volume 16373 1 Year 339.75 13.76
52 Week High 2870.00
52 Week Low 2020.00
GLAXO Important Levels
Resistance 2 2885.84
Resistance 1 2854.14
Pivot 2797.97
Support 1 2763.67
Support 2 2731.96
NSE INDIA Most Active Stocks
RCOM 14.70 -1.34%
JPASSOCIAT 17.25 2.37%
IDBI 58.90 1.99%
PNB 81.90 -1.80%
SUZLON 7.70 0.65%
IDFCBANK 42.05 -1.06%
SBIN 273.05 1.64%
ICICIBANK 300.65 0.91%
BANKBARODA 121.50 -0.41%
ITC 265.15 1.65%
More..
NSE INDIA Top Gainers Stocks
RAJRAYON 0.25 25.00%
CELESTIAL 13.85 19.91%
ADSL 19.55 18.48%
NDGL 1446.45 16.77%
SUJANAUNI 0.55 10.00%
WEIZFOREX 530.50 9.99%
ELAND 8.95 9.82%
TREEHOUSE 10.75 9.69%
ASTRAZEN 1474.25 9.20%
FMGOETZE 446.00 8.74%
More..
NSE INDIA Top Losers Stocks
HIKAL 157.60 -31.82%
UVSL 0.15 -25.00%
MVL 0.25 -16.67%
MVL 0.25 -16.67%
SOMICONVEY 48.40 -11.68%
DUCON 21.95 -11.31%
METKORE 2.00 -9.09%
BIGBLOC 133.50 -7.74%
ZENITHBIR 0.60 -7.69%
RENUKA 13.45 -6.60%
More..

GlaxoSmithKline Pharmaceuticals Limited (NSE: GLAXO)

GLAXO Technical Analysis 5
As on 22nd Jun 2018 GLAXO Share Price closed @ 2808.90 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 2441.24 & Strong Buy for SHORT-TERM with Stoploss of 2468.77 we also expect STOCK to react on Following IMPORTANT LEVELS.
GLAXO Target for June
1st Target up-side 2680.62
2nd Target up-side 2774.34
3rd Target up-side 2868.06
1st Target down-side 2413.18
2nd Target down-side 2319.46
3rd Target down-side 2225.74
GLAXO Synopsis Technicals View
50 Day EMA Close is Above EMA 50 (Short Term)
Bullish
100 Day EMA Close is Above EMA 100 (Mid Term) Bullish
200 Day EMA Close is Above EMA 200 (Long Term) Bullish
MACD (12 26 9) MACD Line is Grater Then SIGNAL Line Bullish
RSI (14) RSI is Above 70 Over Bought
MFI (14) MFI is Above 80 Over Bought
CCI (20) CCI is 87.35 Sideways
WILLIAM %R (14) William %R is Above -20 Over Bought
ADX (14) ADX is Above 20 & +DI is Above -DI Up Trend
PSAR Stoploss For Long Buy 2742.13
10 Day Avg Volume Traded -29.92 % Less then 10 Day Average Volume
GLAXO Other Details
Segment EQ
Market Capital 94531387392.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.gsk-india.com
GLAXO Address
GLAXO
Dr. Annie Besant Road
Mumbai, 400030
India
Phone: 91 22 2495 9595
Fax: 91 22 2495 9494
GLAXO Latest News
IPO Report: SteadyMed (STDY)   Equities.com   - 20th Mar 15
Pharmaceutical, Biotech Mergers Set Record in 2014   Pharmaceutical Processing   - 19th Mar 15
A Decade Old Drug Launch In China With Important Insights Today   Forbes   - 18th Mar 15
MGM and Black Diamond Are Big Market Movers   New York Times   - 17th Mar 15
Business news in brief   Philly.com   - 14th Mar 15
India's Sun Pharma to buy GSK's opiates business in Australia   Reuters   - 03rd Mar 15
GSK Pharma to move cancer drug portfolio to Novartis arm   Moneycontrol.com   - 12th Feb 15
GlaxoSmithKline Pharmaceuticals Ltd clarifies on CCI nod   Equity Bulls   - 26th Dec 14
CCI clears Novartis-GSK pharma deal   Moneycontrol.com   - 23rd Dec 14
GlaxoSmithKline Pharmaceuticals Announces Q3 Results   Business Wire India (press release)   - 06th Nov 14
Interactive Technical Analysis Chart GlaxoSmithKline Pharmaceuticals Limited ( GLAXO NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on GlaxoSmithKline Pharmaceuticals Limited
GLAXO Business Profile
Incorporated in 1924 as H J Foster and Co, Glaxo India became a wholly-owned subsidiary of Joseph Nathan and Co., UK. Later in 1947, the company was renamed as Glaxo Laboratories (India). In 2000, Glaxo Wellcome plc and SmithKline plc merged under an agreement to form a new company, named GlaxoSmithKline plc. With this merger, Glaxo India is now an affiliate of GlaxoSmithKline plc, which holds 51 per cent of the equity. Its principal products are, Betamethasone based topical steroids, Betnovate-C, Betnovate-M, and Betnovate- GM. It also makes tablets from the same pharmaceutical ingredient, which is marketed under the brand name Betnesol. Its other key products are Cephalosporin, Ceftum, H2 blocker based on Ranitidine, Zinetac and the vitamin Celin. Glaxo manufactures the bulk drug from the basic stage, furfuryl alcohol, employing the technology developed by its parent, Glaxo Wellcome, UK. The company also markets over-the-counter (OTC) medicines, dental products, smoking control products and nutritional healthcare drinks. Occupying a 6.5 per cent market share (2005), the company has Biddle Sawyer as its subsidiary. The company recently launched four new products licensed from companies in the US and Japan viz. Parit (Rabeprazole) in alliance with Eisai, Japan, Ferronine (a novel chelated iron) in alliance with Albion, USA and two new oral contraceptives in alliance with Organon. GSK plans to focus on the development of new technologies for Betamethasone, Clobetasone, Clobetasol and collaborative research work with GlaxoSmithKline - R&D, UK. The current market capitalization stands at Rs 20,328.72 crore. The company has reported a standalone sales of Rs 626.65 crore and a Net Profit of Rs 100.95 crore for the quarter ended September 2013. The company management includes D S Parekh - Chairman, V Thyagarajan - Vice Chairman, H B Joshipura - Managing Director, R R Bajaaj - Director, S Harford - Director, M B Kapadia - Director, P V Bhide - Director, R Krishnaswamy - Director, P V Nayak - Director, A N Roy - Director, R C Sequeira - Director, Anjali P Bansal - Ind. Non-Executive Director. The Registered office is at Dr. Annie Besant Road , Mumbai, Maharashtra - 400030.